

FARMASI KLINIS PENYAKIT KRONIS

Dr. apt. Diniatik, S.Si., M.Sc., dkk.
Editor: Nurul Rahmadesni, S.Hum.



Farmasi Klinis Penyakit Kronis

Dr. apt. Diniatik, S.Si., M.Sc., dkk.

Editor: Nurul Rahmadesni, S.Hum.

PT CIPTA DIGITAL EDUKASI

Anggota IKAPI: No. 666/DKI/2026



Farmasi Klinis Penyakit Kronis

Penulis : Dr. apt. Diniatik, S.Si., M.Sc., Apt. Tessa Amanda Primadhini, S.Farm., M.Farm., apt. Cici Feronika, M.Farm., Apt. Yusnita Usman, S.Si., M.Si., apt. Nabila Apriliani, S.Farm., M.Farm., apt. Ryeska Fajar Respaty, S.Farm., M.Farm., apt. Wulan Panduwi Melasari, S.Farm., M.Farm.Klin., apt. Alfiana Pramasita Gonibala, M.Farm., dan apt. Yusrinie Wasiaturrahmah, S.Farm., M.Farm.

ISBN : 978-634-7808-69-1 (PDF)

Penyunting Naskah : Nurul Rahmadesni, S.Hum.

Tata Letak : Nurul Rahmadesni, S.Hum.

Desain Sampul : Novikean Keysah Sanisri

Penerbit

PT Cipta Digital Edukasi

Jl. Wijaya Ii/Wijaya Grand Centre Blok G-15, Desa/Kelurahan Pulo, Kec. Kebayoran Baru, Kota Adm. Jakarta Selatan, Provinsi DKI Jakarta, Kode Pos: 1216

E-Mail : penerbitcde@gmail.com

Website : cideka.com

© Hak cipta dilindungi oleh undang-undang

Berlaku selama 50 (lima puluh) tahun sejak Ciptaan tersebut pertama kali dilakukan pengumuman.

Dilarang mengutip atau memperbanyak sebagian atau seluruh isi buku ini tanpa izin tertulis dari penerbit. Ketentuan Pidana Sanksi Pelanggaran Pasal 2 UU Nomor 19 Tahun 2002 Tentang Hak Cipta.

1. Barang siapa dengan sengaja dan tanpa hak melakukan perbuatan sebagaimana dimaksud dalam Pasal 2 ayat (1) atau Pasal 49 ayat (1) dan ayat (2) dipidana dengan pidana penjara masing-masing paling singkat 1 (satu) bulan dan/atau denda paling sedikit Rp1.000.000,00 (satu juta rupiah), atau pidana penjara paling lama 7 (Tujuh) tahun dan/atau denda paling banyak Rp5.000.000.000,00 (lima miliar rupiah).
2. Barang siapa dengan sengaja menyerahkan, menyiarkan, memamerkan, mengedarkan atau menjual kepada umum suatu Ciptaan atau barang hasil pelanggaran Hak Cipta atau Hak Terkait sebagaimana dimaksud pada ayat (1) dipidana dengan pidana penjara paling lama 5 (lima) tahun dan/atau denda paling banyak Rp500.000.000,00 (lima ratus juta rupiah).

KATA PENGANTAR

Puji syukur ke hadirat Tuhan Yang Maha Esa atas rahmat dan karunia-Nya, sehingga buku berjudul *Farmasi Klinis Penyakit Kronis* dapat disusun sebagai bacaan yang membahas peran farmasi dalam pengelolaan penyakit kronis.

Buku ini menyajikan pembahasan singkat mengenai penggunaan obat, kepatuhan terapi, pemantauan efek obat, serta pentingnya komunikasi pasien dengan tenaga kesehatan. Materi disampaikan dengan bahasa sederhana agar mudah dipahami oleh pembaca.

Buku ini dijual untuk masyarakat umum dan diharapkan dapat membantu pembaca memahami pentingnya farmasi klinis dalam menjaga kualitas hidup penderita penyakit kronis.

Jakarta, Juli 2026

Tim Penyusun

DAFTAR ISI

KATA PENGANTAR	iii
DAFTAR ISI.....	iv
Bab 1: Pengantar Farmasi Klinis Penyakit Kronis.....	1
Apt. Tessa Amanda Primadhini, S.Farm., M.Farm.....	1
1.1 Apa Itu Farmasi Klinis dan Pentingnya dalam Kesehatan	1
1.2 Penyakit Kronis dan Dampaknya pada Kesehatan Masyarakat	5
1.3 Peran Farmasi Klinis dalam Mengelola Penyakit Kronis	9
1.4 Tujuan dan Manfaat Farmasi Klinis Penyakit Kronis	13
Bab 2: Prinsip Terapi Rasional pada Penyakit Kronis.....	18
apt. Cici Feronika, M.Farm.....	18
2.1 Apa Itu Terapi Rasional?.....	18
2.2 Pendekatan Terapi untuk Penyakit Kronis	22
2.3 Menyusun Rencana Pengobatan yang Tepat.....	25
2.4 Tantangan dan Solusi dalam Terapi Penyakit Kronis	29
Bab 3: Manajemen Terapi Hipertensi	33
Apt. Yusnita Usman, S.Si., M.Si.	33
3.1 Mengenal Hipertensi dan Penyebabnya	33
3.2 Pengobatan yang Efektif untuk Hipertensi.....	37

3.4 Strategi Manajemen Terapi Hipertensi yang Berkelanjutan	41
Bab 4: Farmasi Klinis pada Diabetes Melitus.....	45
apt. Nabila Apriliani, S.Farm., M.Farm.	45
4.1 Apa Itu Diabetes Melitus dan Dampaknya?	45
4.2 Pengelolaan Diabetes Melitus dengan Obat-Obatan	50
4.3 Menjaga Kadar Gula Darah dengan Pengobatan	53
4.4 Tantangan dalam Terapi Diabetes dan Solusinya	57
Bab 5: Farmasi Klinis pada Dislipidemia dan Penyakit Kardiovaskular	62
apt. Ryeska Fajar Respaty, S.Farm., M.Farm.	62
5.1 Memahami Dislipidemia dan Penyakit Kardiovaskular.....	62
5.2 Terapi Obat untuk Mengelola Dislipidemia.....	71
5.3 Peran Farmasi Klinis dalam Penyakit Kardiovaskular.....	87
5.4 Menyusun Rencana Pengobatan untuk Kesehatan Jantung .	92
5.5 Skenario Kasus Klinis	94
Bab 6: Farmasi Klinis pada Penyakit Ginjal Kronis	99
apt. Ryeska Fajar Respaty, S.Farm.	99
6.1 Apa Itu Penyakit Ginjal Kronis?	99
6.2 Pengobatan untuk Menjaga Fungsi Ginjal	107
6.3 Peran Farmasi Klinis dalam Penyakit Ginjal	113
6.4 Manajemen Komplikasi Penyakit Ginjal Kronis.....	122

6.5 Penanganan Pasien dengan Gagal Ginjal Kronis Stadium Akhir.....	128
6.6 Skenario Kasus Klinis	133
Bab 7: Farmasi Klinis pada Penyakit Paru Kronis.....	140
apt. Wulan Panduwi Melasari, S.Farm., M.Farm.Klin.	140
7.1 Penyakit Paru Kronis: Penyebab dan Dampaknya	140
7.2 Pengelolaan Penyakit Paru dengan Pengobatan.....	144
7.3 Obat-obatan yang Digunakan dalam Penyakit Paru.....	148
7.4 Strategi untuk Meningkatkan Kualitas Hidup Pasien.....	152
Bab 8 Farmasi Klinis pada Penyakit Neurologis Kronis	155
Dr. apt. Diniatik, S.Si., M.Sc.	155
8.1 Mengenal Penyakit Neurologis Kronis	155
8.2 Terapi Obat untuk Penyakit Neurologis.....	159
8.3 Pengelolaan Nyeri pada Penyakit Neurologis	162
8.4 Pendekatan Holistik dalam Farmasi Klinis Neurologis	166
Bab 9: Farmasi Klinis pada Penyakit Reumatologi dan Nyeri Kronis	171
Dr. apt. Diniatik, S.Si., M.Sc.	171
9.1 Penyakit Reumatologi: Penyebab dan Pengobatan	171
9.2 Terapi Nyeri pada Penyakit Reumatologi	175
9.3 Peran Obat dalam Mengelola Nyeri Kronis	179

9.4 Menjaga Kesejahteraan Pasien dengan Penyakit Reumatologi	183
Bab 10: Farmasi Klinis pada Kanker dan Terapi Jangka Panjang	187
apt. Alfiana Pramasita Gonibala, M.Farm.	187
10.1 Menyikapi Kanker dan Pengobatannya.....	187
10.2 Pengobatan Kemoterapi	190
10.3 Imunoterapi untuk Pengobatan Kanker	199
10.3 Farmasi Klinis dalam Pengobatan Kanker Jangka Panjang	202
10.4 Peran Farmasis dalam Meningkatkan Kualitas Hidup Pasien Kanker	207
Bab 11: <i>Medication Therapy Management</i> pada Pasien Kronis..	212
apt. Ryeska Fajar Respaty, S.Farm., M.Farm.	212
11.1 Apa Itu <i>Medication Therapy Management</i> (MTM)?	212
11.2 Identifikasi dan Klasifikasi <i>Drug-Related Problems</i> (DRP)	218
11.3 Mengelola Obat-Obatan pada Pasien Penyakit Kronis	228
11.4 Dokumentasi dan Komunikasi dalam MTM	232
11.5 Meningkatkan Kepatuhan Pasien terhadap Pengobatan...	235
11.6 Evaluasi dan Penyesuaian Terapi pada Pasien Kronis	236
11.7 Skenario Kasus Klinis	238

Bab 12: Edukasi Pasien dan Masa Depan Farmasi Klinis dalam Pengobatan Penyakit Kronis	244
apt. Yusrinie Wasiaturrahmah, S.Farm., M.Farm.	244
12.1 Pentingnya Edukasi Pasien dalam Pengobatan Penyakit Kronis	244
12.2 Teknik Mengedukasi Pasien untuk Pengelolaan Penyakit Kronis	248
12.3 Masa Depan Farmasi Klinis dalam Mengelola Penyakit Kronis	252
12.4 Peran Teknologi dalam Farmasi Klinis di Masa Mendatang	256
KUNCI JAWABAN	262
DAFTAR PUSTAKA	304
PROFIL PENULIS	326

DAFTAR PUSTAKA

- Adams, R. D., & Victor, M. (2021). *Principles of neurology* (11th ed.). McGraw-Hill Education.
- Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., ... Bakris, G. L. (2021). Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease (FIGARO-DKD). *Lancet*, 398(10308), 1345–1357.
- Ahmed, A., & Popat, S. (2020). *Immunotherapy in cancer treatment: New strategies and future directions*. *Cancer Therapy Review*, 32(4), 243-252.
- Ahn, J., Kim, Y., & Lee, M. (2021). *Immunotherapy and its side effects in long-term cancer treatment*. *Journal of Cancer Therapy*, 32(4), 456-465.
- Al Mahmud A, Joachim S, Jayaraman PP, Learmonth C, Tyagi S, Forkan ARM, Shuakat M, Wickramasinghe N, Wheeler J, Best S, Trainer A. (2026). *Digital Health Interventions to Support Chronic Disease Management: Systematic Scoping Review*. *JMIR Mhealth Uhealth*. 14:e63742. doi: 10.2196/63742. PMID: 41533959; PMCID: PMC12803440.
- Alfianto, H., & Nasir, R. (2020). Perubahan gaya hidup dalam pengelolaan penyakit reumatologi. *Jurnal Kesehatan Reumatologi*, 14(2), 112-120.

- Fitria, A., & Yanti, N. (2021). Pendekatan psikososial dalam meningkatkan kesejahteraan pasien penyakit reumatologi. *Jurnal Psikologi Klinis*, 9(1), 57-65.
- Alquwaidi, M. K., Alkhadrawi, M. A., Alotaibi, A. M. M., Alharbi, K. J. J., Alqahtani, H. M. H., Alharbi, A. S., ... Alsannat, I. A. I. (2024). The role of clinical pharmacists in chronic disease management: A systematic review. *International Journal of Health Sciences*, 18(1), 1–12.
<https://sciencescholar.us/journal/index.php/ijhs/article/view/15389>
- American Cancer Society. (2021). *Cancer facts & figures 2021*. American Cancer Society.
- American Diabetes Association. (2021). *Standards of medical care in diabetes—2021*. *Diabetes Care*, 44(Suppl 1), S1-S2.
- American Pharmacists Association (APhA) & National Association of Chain Drug Stores Foundation (NACDS). (2008). Medication Therapy Management in Pharmacy Practice: Core Elements of an MTM Service Model (Version 2.0). APhA.
- Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., ... & Ziaecian, B. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. *Circulation*, 140(11), e596–e646.
- Aronoff, G. R., Bennett, W. M., Berns, J. S., Brier, M. E., Kasbekar, N., Mueller, B. A., ... Golper, T. A. (2007). *Drug prescribing in renal failure: Dosing guidelines for adults and children* (5th ed.). American College of Physicians.

- Ashley, C., & Dunleavy, A. (Eds.). (2018). *The renal drug handbook: The ultimate prescribing guide for renal practitioners* (4th ed.). CRC Press.
- Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., ... Filippatos, G. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). *The New England Journal of Medicine*, 383(23), 2219–2229.
- Barker, S., Harrison, D., & Thompson, L. (2020). *Pharmacotherapy in long-term cancer care: An overview of recent advancements*. *Journal of Clinical Oncology*, 38(2), 150-158.
- Baskoro, H. (2021). *Pengaruh faktor medis terhadap hipertensi sekunder*. *Jurnal Kesehatan Indonesia*, 13(2), 35-42.
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., ... & Ballantyne, C. M. (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). *New England Journal of Medicine*, 380(1), 11–22.
- Blum, B. M. (2005). Definition of medication therapy management: Development of profession wide consensus. *Journal of the American Pharmacists Association*, 45(5), 566–572.
- Brown, D. L., & White, K. E. (2020). *Improving care coordination in chronic disease management: A review of the literature*. *Journal of Clinical Practice*, 58(2), 145-150.

Brown, D. L., & White, K. E. (2020). *Improving care coordination in chronic disease management: A review of the literature*. *Journal of Clinical Practice*, 58(2), 145-150.

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. (2023). American Geriatrics Society 2023 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. *Journal of the American Geriatrics Society*, 71(7), 2052–2081.

Calleja, L., Glass, B. D., Cairns, A., & Taylor, S. (2023). Pharmacist-led interventions for medication adherence in patients with chronic kidney disease: A scoping review. *Pharmacy*, 11(6), 185. <https://doi.org/10.3390/pharmacy11060185>

Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., ... & Braunwald, E. (2015). Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). *New England Journal of Medicine*, 372(25), 2387–2397.

Carroll, W. L., Devidas, M., & Raetz, E. A. (2014). NIH Public Access, 60(6), 957–963. <https://doi.org/10.1002/pbc.24420>. Children

Carter, J. S., & Phillips, R. L. (2020). *Chronic disease management: A review of recent studies*. *Journal of Chronic Disease Management*, 17(3), 212-225.

Chisholm-Burns, M. A., Graff Zivin, J. S., Lee, J. K., Spivey, C. A., Slack, M., Herrier, R. N., ... & Wunz, T. (2010). Economic effects of pharmacists on health outcomes in the United States:

- A systematic review. *American Journal of Health-System Pharmacy*, 67(19), 1624–1634.
- Chisholm-Burns, M. A., Kim Lee, J., Spivey, C. A., Slack, M., Herrier, R. N., Hall-Lipsy, E., ... & Wunz, T. (2010). US Pharmacists' Effect as Team Members on Patient Care: Systematic Review and Meta-Analyses. *Medical Care*, 48(10), 923–933.
- Cholesterol Treatment Trialists' (CTT) Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*, 376(9753), 1670–1681.
- Cipolle, R. J., Strand, L. M., & Morley, P. C. (2012). *Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services* (3rd ed.). McGraw-Hill Education.
- Co, W., Feng, L., Smith-Ray, R., et al. (2024). Pharmacists as clinical care partners: How a pharmacist-led intervention is associated with improved medication adherence in older adults with common chronic conditions. *Journal of Managed Care & Specialty Pharmacy*, 30(4), 345–354. <https://doi.org/10.18553/jmcp.2024.30.4.345>
- Cushman, W. C., Evans, G. W., Byington, R. P., Goff, D. C., Jr., Grimm, R. H., Jr., Cutler, J. A., ... Simons-Morton, D. G. (2010). Effects of intensive blood-pressure control in type 2 diabetes mellitus (ACCORD-BP). *The New England Journal of Medicine*, 362(17), 1575–1585.

- David, D., & Szentagotai, A. (2021). The efficacy of rational emotive behavior therapy: A meta-analysis of randomized controlled trials. *Journal of Cognitive Psychotherapy*, 35(2), 92-103.
- DiPiro, J. T., Yee, G. C., Posey, L. M., Haines, S. T., Nolin, T. D., & Ellingrod, V. (Eds.). (2023). *Pharmacotherapy: A Pathophysiologic Approach* (12th ed.). McGraw-Hill Education.
- Dirgambiro R.A., & Parwanto, E. (2024). *Prinsip Terapi Kanker*. Penerbit Underline. Klaten.
- Dixon, D. L., Parod, E. D., Engel, J. S., Granger, B. B., & Sánchez, M. J. (2020). A Pharmacist-Led Lipid Clinic: A Systematic Review. *Pharmacotherapy*, 40(3), 220–233.
- Duarte, P. (2021). *Diabetes management: Pharmacological treatments and their effects on blood glucose control*. *Journal of Diabetes Science and Technology*, 15(1), 32-41.
- Ellis, A. (2020). *Rational emotive behavior therapy: A therapist's guide* (3rd ed.). Springer Publishing.
- Farhana, L., Rahayu, F. P., Sholihah, S., Sweileh, W., Abdulah, R., & Alfian, S. D. (2025). Effectiveness of pharmacist-led intervention on medication adherence in chronic diseases: A systematic review of randomized controlled trials. *Patient Preference and Adherence*, 19, 2161–2178. <https://doi.org/10.2147/PPA.S530503>

- Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., & Rosenfeld, W. (2020). *Pharmacologic therapy for epilepsy: Current and emerging options*. *Epilepsia*, 61(2), 284-294.
- Gage, F. H. (2020). *Neurogenesis in the adult brain*. Academic Press.
- Galmarini E, Marciano L, Schulz PJ. (2024). *The effectiveness of visual-based interventions on health literacy in health care: a systematic review and meta-analysis*. *BMC Health Serv Res*. ;24(1):718. doi: 10.1186/s12913-024-11138-1. PMID: 38862966; PMCID: PMC11165863.
- Garofalo, M., Vetro, C., & Shimizu, K. (2021). *Targeted therapy in oncology: The role of tyrosine kinase inhibitors*. *Journal of Cancer Treatment*, 35(2), 87-98.
- Global Burden of Disease Collaborative Network. (2024). *Global Burden of Disease Study 2021 (GBD 2021) results*. Institute for Health Metrics and Evaluation. <https://vizhub.healthdata.org/gbd-results/>
- Greer N, Bolduc J, Geurkink E, et al. (2015). *Pharmacist-Led Chronic Disease Management: A Systematic Review of Effectiveness and Harms Compared to Usual Care* . Washington (DC): Department of Veterans Affairs (US). Available from: <https://www.ncbi.nlm.nih.gov/books/NBK362938/>
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., ... & Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood

- Cholesterol. *Journal of the American College of Cardiology*, 73(24), e285–e350.
- Hacker, K. (2024). The burden of chronic disease. *Mayo Clinic Proceedings: Innovations, Quality & Outcomes*, 8(1), 112–119. <https://doi.org/10.1016/j.mayocpiqo.2023.08.005>
- Hadi, S. (2021). *Obat-obat dalam pengelolaan penyakit paru*. *Jurnal Kesehatan Paru*, 14(2), 45-51.
- Hadi, S. (2021). *Pendekatan terapi kombinasi dalam pengelolaan nyeri kronis*. *Jurnal Nyeri*, 11(2), 105-112.
- Haleem, A., et al. (2021). *Telemedicine for healthcare: Capabilities, features, barriers, and applications*. *Sensors International*, 2, 100117.
- Hanlon, J. T., & Schmader, K. E. (2013). The Medication Appropriateness Index at 20: Where it started, where it has been, and where it may be going. *Drugs & Aging*, 30(11), 893–900.
- Harvey, R. A. & Champe, P.C., 2013, *Farmakologi Ulasan Bergambar*, Edisi 4, C. Ramadhani, Dian [et al], Tjahyanto, Adhi, Salim, ed., Jakarta, Buku Kedokteran EGC.
- Hepler, C. D., & Strand, L. M. (1990). Opportunities and responsibilities in pharmaceutical care. *American Journal of Hospital Pharmacy*, 47(3), 533–543. <https://doi.org/10.1093/ajhp/47.3.533>
- Hernandez, A., Garcia, M., & Lopez, S. (2020). *Physical activity and blood glucose control in type 2 diabetes: An overview of exercise interventions*. *Diabetes Care*, 43(9), 2009-2017.

- Herrington, W. G., Staplin, N., Wanner, C., Green, J. B., Hauske, S. J., Emberson, J. R., ... Baigent, C. (2023). Empagliflozin in patients with chronic kidney disease (EMPA-KIDNEY). *The New England Journal of Medicine*, 388(2), 117–127.
- Hibbard, J. H., & Greene, J. (2020). *What the evidence shows about patient activation: Better health outcomes and care experiences; fewer data on costs*. *Health Affairs*, 39(7), 1206-1213.
- Hidayat, T., & Sari, N. (2020). Perubahan gaya hidup sehat untuk peningkatan kualitas hidup pasien dengan penyakit kronis. *Jurnal Kesehatan Masyarakat*, 21(2), 119-126.
- Horne, R., Weinman, J., & Hankins, M. (1999). The Beliefs about Medicines Questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology & Health*, 14(1), 1–24.
- Howie-Esquivel J, Bidwell JT. (2023). *A State-of-the-Art Review of Teach-Back for Patients and Families With Heart Failure: How Far Have We Come?* J Cardiovasc Nurs. :10.1097/JCN.0000000000000980. doi: 10.1097/JCN.0000000000000980. Epub ahead of print. PMID: 36881405; PMCID: PMC10480340.
- Hu, F. B., & Manson, J. E. (2020). Obesity and type 2 diabetes: The role of lifestyle modification. *Current Diabetes Reports*, 20(5), 129-134.
- Ikatan Apoteker Indonesia. (2020). *Standar kompetensi apoteker Indonesia*. Pengurus Pusat Ikatan Apoteker Indonesia.

Institute for Health Metrics and Evaluation. (2024). *New Global Burden of Disease Study: Mortality declines, youth deaths rise, widening health inequities*. University of Washington. <https://www.healthdata.org/news-events/newsroom/news-releases/new-global-burden-disease-study-mortality-declines-youth-deaths>

International Agency for Research on Cancer, and World Health Organization. Globocan, cancer today. Data visualization tools for exploring the global cancer burden in 2022 [Internet]. 2024 [cited on Jan 10, 2025].

International Diabetes Federation. (2024). *IDF Diabetes Atlas* (11th ed.). International Diabetes Federation. <https://diabetesatlas.org/>

Isetts, B. J., Schondelmeyer, S. W., Artz, M. B., Lenarz, L. A., Heaton, A. H., Wadd, W. B., ... & Cipolle, R. J. (2008). Clinical and economic outcomes of MTM services: The Minnesota experience. *Journal of the American Pharmacists Association*, 48(2), 203–214.

Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2020). Global cancer statistics. *CA: A Cancer Journal for Clinicians*, 70(1), 7-30.

Johnson, T. (2020). *Social support and recovery outcomes in chronic illness management*. *Journal of Health Psychology*, 25(4), 567-578.

Kang, J., Kim, H. S., Park, S. J., Lee, S. W., ... & Park, D. W. (2022). Attainment of Lipid Goals in Real-World Practice in Asian

- Patients with Atherosclerotic Cardiovascular Disease. *Atherosclerosis*, 349, 53–61.
- Katzenschlager, R., Lees, A. J., & Olanow, C. W. (2020). *Parkinson's disease: Current therapies and the role of dopaminergic medication*. *Neurology*, 94(6), 244-256.
- KDIGO Anemia Work Group. (2012). KDIGO clinical practice guideline for anemia in CKD. *Kidney International Supplements*, 2(4), 279–335.
- KDIGO CKD-MBD Work Group. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. *Kidney International Supplements*, 7(1), 1–59.
- Kementerian Kesehatan Republik Indonesia. (2016). Peraturan Menteri Kesehatan Nomor 72 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Rumah Sakit. Kemenkes RI.
- Kementerian Kesehatan Republik Indonesia. (2016). Peraturan Menteri Kesehatan Nomor 74 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Puskesmas. Kemenkes RI.
- Kementerian Kesehatan Republik Indonesia. (2021). *Pedoman nasional pelayanan kedokteran: Penyakit ginjal kronis*. Kementerian Kesehatan Republik Indonesia.
- Kemp, L. (2021). *Pharmacological approaches to the management of chronic diseases*. *Journal of Medical Sciences*, 22(4), 198-209.

- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney International Supplements*.
- Koda-Kimble, M. A., & Young, L. Y. (2021). *Applied Therapeutics: The Clinical Use of Drugs* (12th ed.). Wolters Kluwer.
- Kripalani, S., Risser, J., Gatti, M. E., & Jacobson, T. A. (2009). Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. *Value in Health*, 12(1), 118–123.
- Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., ... & Catapano, A. L. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *European Heart Journal*, 43(39), 3925–3946.
- Kurniawan, M. (2020). *Peran terapi antikolinergik dalam penyakit paru obstruktif kronik*. Jurnal Farmasi Klinis, 19(3), 125-133.
- Kusnadi, K., & Rahmawati, S. (2020). Pengelolaan terapi hipertensi yang optimal: Pendekatan farmakologis dan non-farmakologis. *Jurnal Ilmu Kesehatan*, 12(3), 150-158.
- Kusuma, R. (2020). *Peran obat antikonvulsan dan antidepresan dalam nyeri neuropatik*. Jurnal Farmasi Klinis, 18(3), 45-53.
- Kusumaningrum, D., & Wijaya, A. (2021). Peran gaya hidup sehat dalam pencegahan penyakit kronis di Indonesia. *Jurnal Kesehatan Masyarakat*, 12(2), 123-135.

- Kusumaningrum, D., & Wijaya, A. (2021). Peran gaya hidup sehat dalam pencegahan penyakit kronis di Indonesia. *Jurnal Kesehatan Masyarakat*, 12(2), 123-135.
- Kusumaningrum, D., & Wijaya, A. (2021). Peran gaya hidup sehat dalam pencegahan penyakit kronis di Indonesia. *Jurnal Kesehatan Masyarakat*, 12(2), 123-135.
- Kwan, J. L., Lo, L., Sampson, M., & Shojania, K. G. (2013). Medication reconciliation during transitions of care as a patient safety strategy: A systematic review. *Annals of Internal Medicine*, 158(5 Pt 2), 397–403.
- Lestari, A., & Pramudya, Y. (2021). Pendekatan psikososial dalam meningkatkan kualitas hidup pasien. *Jurnal Psikologi Klinis*, 8(3), 45-52.
- Macdougall, I. C., White, C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., ... Parfrey, P. (2019). Intravenous iron in patients undergoing maintenance hemodialysis (PIVOTAL). *The New England Journal of Medicine*, 380(5), 447–458.
- Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., ... & Wiklund, O. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *European Heart Journal*, 41(1), 111–188.
- Mahalingam, S., & Coyle, M. (2020). *Cellular and genetic therapies for cancer: CAR-T cells and beyond*. *Journal of Oncological Research*, 44(5), 403-415.

- McCarthy, D., Wanat, M., & Surbhi, S. (2022). Impact of pharmacist-led chronic disease management in a federally qualified health center. *JACCP: Journal of the American College of Clinical Pharmacy*, 5(11), 1201–1210. <https://doi.org/10.1002/jac5.1720>
- Miller, D. H., Chard, D. T., & Ciccarelli, O. (2021). *Multiple sclerosis: Current treatment strategies and future directions*. The Lancet Neurology, 20(1), 77-91.
- Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005). Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. *Annals of Internal Medicine*, 142(1), 37–46.
- Miller, R. S., Anderson, C. L., & Davis, G. P. (2020). *Neurogenic pain in neurological disorders: Pathophysiology and management*. Journal of Pain Management, 25(4), 58-67.
- Morisky, D. E., Ang, A., Krousel-Wood, M., & Ward, H. J. (2008). Predictive validity of a medication adherence measure in an outpatient setting. *Journal of Clinical Hypertension*, 10(5), 348–354. [Catatan: Penggunaan MMAS-8 memerlukan lisensi dari pencipta.]
- Murtagh, F. E. M., Marsh, J. E., Donohoe, P., Ekbal, N. J., Sheerin, N. S., & Harris, F. E. (2007). Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. *Nephrology Dialysis Transplantation*, 22(7), 1955–1962.

- Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., ... & Nicholls, S. J. (2023). Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes). *New England Journal of Medicine*, 388(15), 1353–1364.
- O'Mahony, D., Cherubini, A., Guiteras, A. R., Denking, M., Beuscart, J. B., Onder, G., ... & Gallagher, P. (2023). STOPP/START criteria for potentially inappropriate prescribing in older people: Version 3. *European Geriatric Medicine*, 14(3), 625–632.
- Pavithra, S., Mazumder, A., Dharani, V., Hiremath, S. R., & Vaidya, R. (2026). Impact of community pharmacist interventions on medication adherence in chronic disease patients: Systematic review and meta-analysis. *Journal of Community Pharmacy Practice*, 6(1). <https://doi.org/10.55540/2993-2696.1107>
- Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Rumah Sakit. (2016). Kementerian Kesehatan Republik Indonesia.
- Perhimpunan Dokter Hipertensi Indonesia (InaSH). (2019). *Konsensus Penatalaksanaan Hipertensi 2019*. InaSH.
- Perhimpunan Nefrologi Indonesia. (2022). *Konsensus tata laksana penyakit ginjal kronis*. PERNEFRI.
- Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., ... Mahaffey, K. W. (2019). Canagliflozin and renal outcomes in type 2 diabetes and

- nephropathy (CREDENCE). *The New England Journal of Medicine*, 380(24), 2295–2306.
- Perkovic, V., Tuttle, K. R., Engkilde, K., Fernandez, E., Gao, P., Goldber, T., ... Mann, J. F. E. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). *The New England Journal of Medicine*, 391(2), 109–121.
- Perkumpulan Endokrinologi Indonesia (PERKENI). (2021). *Pedoman Pengelolaan Dislipidemia di Indonesia 2021*. PB PERKENI.
- Pharmaceutical Care Network Europe (PCNE). (2020). *PCNE Classification for Drug-Related Problems V9.1*. Available at: www.pcne.org.
- Pindolia, V. K., Stebelsky, L., Romain, T. M., Lupo, L., Nowak, S. N., & Gillanders, F. (2009). Mitigation of medication mishaps via medication therapy management. *Annals of Pharmacotherapy*, 43(4), 611–620.
- Prabowo, T. (2021). *Faktor genetik dalam perkembangan penyakit reumatologi autoimun*. *Jurnal Reumatologi*, 13(2), 124-130.
- Pradipta, A. (2021). *Studi tentang penyebab dan dampak hipertensi primer*. *Jurnal Penyakit Dalam*, 28(3), 215-221.
- Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., ... & Landmesser, U. (2020). Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10 and ORION-11). *New England Journal of Medicine*, 382(16), 1507–1519.

- Reis, S. (2024). Clinical pharmacy in chronic disease management. *Journal of Applied Pharmacy*, 16(2), 408. <https://doi.org/10.35248/1920-4159.24.16.408>
- Rosenblum, E., & Lee, D. (2020). *Insulin therapy in type 1 diabetes: New insights and management strategies*. *Journal of Diabetes Therapy*, 15(2), 112-124.
- Ruhyandudin, F., Theresia, M. W., & Azalia, N. R. (2022). Analisis terapi pilihan untuk mengurangi keluhan subyektif pada pasien kanker yang menjalani kemoterapi. *Jurnal Keperawatan Muhammadiyah*, 7(3).
- Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., ... & Braunwald, E. (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). *New England Journal of Medicine*, 376(18), 1713–1722.
- Sakinah, G., Afriani, W., Widya, S. A., & Faturrahman, F. A. (2025). Analisis Jenis-Jenis Kanker Terbesar di Indonesia Dengan Model SIR. *Jurnal Riset Mahasiswa Matematika*, 4(4), 161-168.
- Salim, I. (2020). *Pengobatan penyakit reumatologi: Pendekatan farmakologis dan terapi fisik*. *Jurnal Kesehatan Reumatologi*, 22(1), 56-62.
- Sánchez-Bayona R, Catalán C, Cobos MA, Bergamino M. (2025). *Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications*.

- Cancers (Basel).;17(6):913. doi: 10.3390/cancers17060913. PMID: 40149251; PMCID: PMC11939999.
- Sari, D., & Yuliana, R. (2020). Terapi medis dalam pengelolaan penyakit reumatologi. *Jurnal Ilmu Reumatologi*, 8(3), 145-152.
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., ... & Bhatt, D. L. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). *New England Journal of Medicine*, 379(22), 2097–2107.
- Scott, I. A., Hilmer, S. N., Reeve, E., Potter, K., Le Couteur, D., Rigby, D., ... & Martin, J. H. (2015). Reducing inappropriate polypharmacy: The process of deprescribing. *JAMA Internal Medicine*, 175(5), 827–834.
- Seprian, D., & Puspitosari, W. A. (2019). Regulasi Emosi dalam Tatalaksana Pasien Kanker: A Literatur Review. *Jurnal Keperawatan Respati Yogyakarta*, 6(2), 597-605.
- Setiawan, B. (2021). Pengaruh kebiasaan merokok terhadap perkembangan penyakit paru kronis. *Jurnal Paru-paru*, 12(3), 45-52.
- Setiawan, M., & Widodo, S. (2020). Pemantauan terapi hipertensi: Evaluasi berkala dan pengelolaan yang efektif. *Jurnal Kardiologi Indonesia*, 24(2), 101-110.
- Smith, A. J. (2021). *Patient adherence in chronic disease management: Challenges and solutions*. *Journal of Health Communication*, 35(3), 225-230.

- Smith, R. (2021). *Shared decision-making in clinical practice: Enhancing patient involvement*. *Medical Decision Making*, 41(2), 215-223.
- Strand, L. M., Morley, P. C., Cipolle, R. J., Ramsey, R., & Lamsam, G. D. (1990). Drug-related problems: their structure and function. *DICP*, 24(11), 1093–1097.
- Supriyadi, D. (2020). *Pola hidup sehat dalam pencegahan hipertensi*. *Jurnal Kesehatan Masyarakat*, 17(1), 102-109.
- Sutaryo, E., & Prasetyo, S. (2020). Pengaruh penyakit jantung terhadap kualitas hidup masyarakat di perkotaan. *Jurnal Kedokteran Indonesia*, 15(3), 50-59.
- Sutrisno, H. (2020). *Obat-obatan untuk pengelolaan nyeri kronis: NSAIDs dan opioid*. *Jurnal Medik*, 19(4), 67-74.
- Sutrisno, H. (2020). *Penggunaan kortikosteroid dalam pengobatan penyakit paru*. *Jurnal Medis*, 22(1), 87-94.
- Sutrisno, H. (2021). *Bronkodilator dan pengelolaan penyakit paru kronis*. *Jurnal Farmasi Klinis*, 20(4), 178-185.
- Sutrisno, H. (2021). *Penggunaan opioid dalam nyeri kronis: Risiko dan manfaat*. *Jurnal Farmasi Klinis*, 20(1), 33-40.
- Sweeney, D., & Pike, J. (2021). *Pharmacological management of type 2 diabetes: Current options and future directions*. *Diabetes Care Review*, 33(4), 76-85.
- Takimoto, C. H., & Calvo, E. (2008). Principles of oncologic pharmacotherapy. *Cancer management: a multidisciplinary approach*, 11, 1-9.

- Tangri, N., Grams, M. E., Levey, A. S., Coresh, J., Appel, L. J., Astor, B. C., ... Inker, L. A. (2016). Multinational assessment of accuracy of equations for predicting risk of kidney failure (KFRE). *JAMA*, 315(2), 164–174.
- Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., ... & Stroes, E. S. G. (2018). NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. *Journal of the American College of Cardiology*, 71(2), 177–192.
- Tsuyuki, R. T., Al Hamarneh, Y. N., Jones, C. A., & Hemmelgarn, B. R. (2016). The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled Rx EACH Trial. *Journal of the American College of Cardiology*, 67(24), 2846–2854.
- Tsuyuki, R. T., Al Hamarneh, Y. N., Jones, C. A., & Hemmelgarn, B. R. (2016). The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled Rx EACH Trial. *Journal of the American College of Cardiology*, 67(24), 2846–2854.
- Visseren, F. L. J., Mach, F., Smulders, E. C. D., Carballo, D., Koskinas, K. C., Böck, M., ... & Williams, B. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *European Heart Journal*, 42(34), 3227–3337.

- Wahyu, P., & Rina, M. (2020). Kolaborasi tim medis dalam meningkatkan kualitas hidup pasien dengan kondisi kronis. *Jurnal Kesehatan Indonesia*, 14(4), 98-104.
- Wahyuni, T. (2020). *Faktor lingkungan dalam perkembangan penyakit paru kronis*. *Jurnal Kesehatan Lingkungan*, 19(4), 302-310.
- Wang, X. (2020). *Interdisciplinary approaches in healthcare: Improving patient outcomes through collaboration*. *Journal of Collaborative Healthcare*, 15(3), 120-130.
- Wanner, C., Amann, K., & Shafi, T. (2016). The heart and vascular system in dialysis. *Lancet*, 388(10041), 276–284.
- Wheeler, D. C., Stefansson, B. V., Batiushin, M., Bhatt, D. L., Cain, V., Chen, C. Y., ... Heerspink, H. J. L. (2021). The dapagliflozin and prevention of adverse outcomes in CKD trial (DAPA-CKD). *Kidney International*, 100(1), 215–224.
- WHO High 5s Project. Medication Reconciliation. Available at: www.who.int/patientsafety.
- Williams, H. A., & Thomas, D. W. (2020). *Pharmacological and non-pharmacological approaches in managing neuropathic pain*. *Journal of Neurological Therapy*, 18(2), 134-141.
- Williams, L., & Zhang, Y. (2020). *The role of continuous glucose monitoring in managing type 2 diabetes*. *Journal of Diabetes Technology*, 14(2), 153-161.
- World Health Organization, (2022). Insiden dan Prevalensi Kanker di Indonesia. [360-indonesia-fact-sheet.pdf](https://www.who.int/publications-detail/360-indonesia-fact-sheet)

- World Health Organization. (2003). *Adherence to Long-Term Therapies: Evidence for Action*. WHO Press.
- World Health Organization. (2024). *Noncommunicable diseases: Key facts*. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>
- Yuliana, D., & Wulan, W. (2024). Literature Review: Perkembangan Pengobatan Kemoterapi Kanker Payudara. *Makassar Pharmaceutical Science Journal (MPSJ)*, 2(1), 32-40
- Yulianto, F., & Hasanah, N. (2021). Pengaruh gaya hidup terhadap pengelolaan hipertensi di masyarakat. *Jurnal Kesehatan Masyarakat*, 18(1), 85-94.
- Zhang, Y., Yang, H., & Wang, Z. (2021). *Pharmacological interventions for Alzheimer's disease: Current status and future directions*. *Journal of Clinical Neurology*, 17(2), 123-134.

Buku ***Farmasi Klinis Penyakit Kronis*** membahas peran obat dalam penanganan berbagai penyakit jangka panjang, seperti diabetes, hipertensi, gangguan jantung, asma, dan penyakit kronis lainnya. Isi buku disajikan dengan bahasa yang mudah dipahami agar pembaca dapat mengenali pentingnya penggunaan obat secara tepat, teratur, dan aman.

Buku ini juga membantu pembaca memahami pemantauan terapi, risiko efek samping, serta pentingnya kerja sama antara pasien, keluarga, apoteker, dan tenaga kesehatan. Buku ini dijual untuk masyarakat umum yang ingin lebih bijak dalam memahami pengobatan penyakit kronis dan menjaga kualitas hidup sehari-hari.